Allergic Alveolitis Clinical Trial
Official title:
Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease
Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood - a randomized,
double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and
course of disease.
The hypothesis of the study is that the treatment with placebo will not be inferior in terms
of Forced Vital Capacity (FVC) improvement than treatment with systemic steroids after 6
months treatment.
Patients will be allocated to the two treatments, i.e., oral prednisolone and Placebo.
Experimental intervention: Placebo Control intervention: Prednisolone Duration of
intervention per patient: 3 months Follow-up per patient: 3 months
Primary Objective:
To evaluate outcome of EAA at 6 months and compare the medium term treatment with systemic
steroids or Placebo.
Secondary Objectives:
To evaluate the completeness and knowledge of standardized and pedantic allergen elimination
in families with a child with EAA.
To evaluate the treatment of EAA with systemic steroids compared to placebo at 3 months.
To evaluate the safety of the treatment of EAA with outpatient usage of systemic steroids
compared to Placebo.
;